CBP501, Cisplatin and Nivolumab in Advanced Refractory Tumors
Status:
Completed
Trial end date:
2021-02-15
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, phase 1b study of CBP501/cisplatin/nivolumab combination
administered once every 21 days to patients with advanced solid tumors.